Segment Information - Reportable Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Segment Reporting Information [Line Items]
Net sales	$ 2,694	$ 2,925	$ 8,301	$ 8,713
Cost of sales	(1,711)	(1,873)	(5,253)	(5,569)
Research & development expenses	(174)	(162)	(520)	(501)
Selling & administrative expenses	(421)	(495)	(1,365)	(1,478)
Adjusted Operating EBITDA		568	1,649	1,734
Depreciation & Amortization	(247)	(248)	(725)	(772)
Interest Expense	(48)	(74)	(180)	(236)
Other expense	(14)	(28)	(44)	(44)
Restructuring Charges	(16)	(1)	(54)	(6)
Impairment	0	0	(1,153)	(64)	$ (64)
Losses (gains) on business disposals	0	(20)	(111)	348
Loss on held for sale classification	(108)	(32)	(108)	(284)
Divestiture And Integration Costs	(13)	(55)	(90)	(172)
Strategic initiative costs	(10)	(6)	(24)	(22)
Regulatory costs	(7)	(10)	(71)	(64)
Gain (loss) on extinguishment of debt	0	0	488	0
Tax realignment costs	(1)		(5)	(3)
Other gains (losses)	1	1	(6)	8
Income before taxes	56	95	(434)	423
Segment capital expenditures	132	103	406	303
Business divestiture costs	13	55	90	167
Integration-related costs				5
Taste
Segment Reporting Information [Line Items]
Restructuring Charges	(9)	0	(17)	(1)
Impairment			0
Food Ingredients
Segment Reporting Information [Line Items]
Restructuring Charges	(2)	0	(12)	(2)
Impairment			(1,153)
Health & Biosciences
Segment Reporting Information [Line Items]
Restructuring Charges	(4)	0	(12)	(1)
Impairment			0
Scent
Segment Reporting Information [Line Items]
Restructuring Charges	(1)	0	(13)	(1)
Impairment			0
Pharma Solutions
Segment Reporting Information [Line Items]
Restructuring Charges	0	(1)	0	(1)
Impairment			0
Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,694	2,925	8,301	8,713
Adjusted Operating EBITDA	519	568	1,649	1,734
Operating Segments | Taste
Segment Reporting Information [Line Items]
Net sales	635	623	1,893	1,852
Cost of sales	(379)	(369)	(1,133)	(1,110)
Research & development expenses	(41)	(38)	(128)	(117)
Selling & administrative expenses	(103)	(103)	(295)	(299)
Depreciation expense add-back (a)	16	16	47	47
Adjusted Operating EBITDA	128	129	384	373
Segment capital expenditures	15	18	57	41
Operating Segments | Food Ingredients
Segment Reporting Information [Line Items]
Net sales	830	843	2,476	2,546
Cost of sales	(642)	(668)	(1,893)	(1,996)
Research & development expenses	(13)	(17)	(39)	(58)
Selling & administrative expenses	(104)	(99)	(300)	(283)
Depreciation expense add-back (a)	(35)	(32)	(97)	99
Adjusted Operating EBITDA	106	91	341	308
Segment capital expenditures	59	34	159	104
Operating Segments | Health & Biosciences
Segment Reporting Information [Line Items]
Net sales	577	568	1,694	1,653
Cost of sales	(315)	(305)	(924)	(885)
Research & development expenses	(57)	(44)	(164)	(140)
Selling & administrative expenses	(87)	(96)	(259)	(273)
Depreciation expense add-back (a)	32	29	92	86
Adjusted Operating EBITDA	150	152	439	441
Operating Segments | Scent
Segment Reporting Information [Line Items]
Net sales	652	613	1,869	1,861
Cost of sales	(374)	(353)	(1,054)	(1,031)
Research & development expenses	(63)	(57)	(180)	(167)
Selling & administrative expenses	(97)	(94)	(275)	(275)
Depreciation expense add-back (a)	(17)	(19)	(49)	51
Adjusted Operating EBITDA	135	128	409	439
Segment capital expenditures	21	18	53	43
Operating Segments | Pharma Solutions
Segment Reporting Information [Line Items]
Net sales		278	369	801
Cost of sales		(178)	(248)	(546)
Research & development expenses		(6)	(8)	(19)
Selling & administrative expenses		(30)	(42)	(84)
Depreciation expense add-back (a)		(4)	(5)	21
Adjusted Operating EBITDA		68	76	173
Segment capital expenditures	0	16	38	63
Operating Segments | Health And Biosciences
Segment Reporting Information [Line Items]
Segment capital expenditures	$ 37	$ 17	$ 99	$ 52